On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a ...

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow ...

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, ...

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with ...

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

A new combination therapy involving belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone showed promising ...

A new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.